358 related articles for article (PubMed ID: 9648926)
21. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.
Tørring N; Jørgensen PE; Sørensen BS; Nexø E
Anticancer Res; 2000; 20(1A):91-5. PubMed ID: 10769639
[TBL] [Abstract][Full Text] [Related]
22. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
23. Epithelial rat thyroid cell clones, escaping from transforming growth factor beta negative growth control, are still inhibited by this factor in the ability to trap iodide.
Coppa A; Mincione G; Mammarella S; Ranieri A; Colletta G
Cell Growth Differ; 1995 Mar; 6(3):281-90. PubMed ID: 7794796
[TBL] [Abstract][Full Text] [Related]
24. Regulation of heparin-binding EGF-like growth factor expression in Ha-ras transformed human mammary epithelial cells.
Martínez-Lacaci I; De Santis M; Kannan S; Bianco C; Kim N; Wallace-Jones B; Wechselberger C; Ebert AD; Salomon DS
J Cell Physiol; 2001 Feb; 186(2):233-42. PubMed ID: 11169460
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
[TBL] [Abstract][Full Text] [Related]
26. Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells.
O-Charoenrat P; Rhys-Evans P; Eccles S
Int J Cancer; 2000 Dec; 88(5):759-65. PubMed ID: 11072245
[TBL] [Abstract][Full Text] [Related]
27. Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes.
Piepkorn M; Predd H; Underwood R; Cook P
Arch Dermatol Res; 2003 Jul; 295(3):93-101. PubMed ID: 12768307
[TBL] [Abstract][Full Text] [Related]
28. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
Bacus SS; Yarden Y; Oren M; Chin DM; Lyass L; Zelnick CR; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli RR; Hynes NE; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K
Oncogene; 1996 Jun; 12(12):2535-47. PubMed ID: 8700512
[TBL] [Abstract][Full Text] [Related]
29. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
30. Loss of growth responsiveness to epidermal growth factor and enhanced production of alpha-transforming growth factors in ras-transformed mouse mammary epithelial cells.
Salomon DS; Perroteau I; Kidwell WR; Tam J; Derynck R
J Cell Physiol; 1987 Mar; 130(3):397-409. PubMed ID: 3494020
[TBL] [Abstract][Full Text] [Related]
31. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
[TBL] [Abstract][Full Text] [Related]
32. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
33. The role of heregulin-alpha as a motility factor and amphiregulin as a growth factor in wound healing.
Schelfhout VR; Coene ED; Delaey B; Waeytens AA; De Rycke L; Deleu M; De Potter CR
J Pathol; 2002 Dec; 198(4):523-33. PubMed ID: 12434423
[TBL] [Abstract][Full Text] [Related]
34. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression.
Sundaresan S; Roberts PE; King KL; Sliwkowski MX; Mather JP
Endocrinology; 1998 Dec; 139(12):4756-64. PubMed ID: 9832411
[TBL] [Abstract][Full Text] [Related]
35. Expression of P185erbB-2, P160erbB-3, P180erbB-4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines.
al Moustafa AE; Alaoui-Jamali M; Paterson J; O'Connor-McCourt M
Anticancer Res; 1999; 19(1A):481-6. PubMed ID: 10226586
[TBL] [Abstract][Full Text] [Related]
36. Differential dependence of the tumorigenicity of chemically transformed rat liver epithelial cells on autocrine production of transforming growth factor alpha.
Duddy SK; Earp HS; Russell WE; Smith GJ; Grisham JW
Cell Growth Differ; 1995 Mar; 6(3):251-61. PubMed ID: 7794793
[TBL] [Abstract][Full Text] [Related]
37. Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro.
Varley C; Hill G; Pellegrin S; Shaw NJ; Selby PJ; Trejdosiewicz LK; Southgate J
Exp Cell Res; 2005 May; 306(1):216-29. PubMed ID: 15878346
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.
Landgraf R; Pegram M; Slamon DJ; Eisenberg D
Biochemistry; 1998 Mar; 37(9):3220-8. PubMed ID: 9485477
[TBL] [Abstract][Full Text] [Related]
39. Amphiregulin as an autocrine growth factor for c-Ha-ras- and c-erbB-2-transformed human mammary epithelial cells.
Normanno N; Selvam MP; Qi CF; Saeki T; Johnson G; Kim N; Ciardiello F; Shoyab M; Plowman G; Brandt R
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2790-4. PubMed ID: 7908443
[TBL] [Abstract][Full Text] [Related]
40. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides.
Normanno N; Bianco C; Damiano V; de Angelis E; Selvam MP; Grassi M; Magliulo G; Tortora G; Bianco AR; Mendelsohn J; Salomon DS; Ciardiello F
Clin Cancer Res; 1996 Mar; 2(3):601-9. PubMed ID: 9816209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
